Detalhe da pesquisa
1.
Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data.
Clin Nephrol
; 97(5): 261-272, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-34931610
2.
Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
BMC Nephrol
; 20(1): 125, 2019 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30971227
3.
Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome.
Kidney Int
; 94(2): 408-418, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29907460
4.
Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis.
Transpl Int
; 30(12): 1275-1283, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28801959